ITUS Corporation (ITUS) Announces Positive Cchek Platform Data in Detecting Melanoma

September 28, 2016 9:06 AM EDT
Get Alerts ITUS Hot Sheet
Trade ITUS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

ITUS Corporation (Nasdaq: ITUS) announced that it has successfully utilized its Cchek early cancer detection platform to identify the presence of Melanoma. Melanoma accounts for the vast majority of skin cancer deaths, which kills approximately 121,000 people per year worldwide.

Cchekâ„¢ is ITUS's early cancer detection technology, which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream. As part of the ongoing development of ITUS's Cchek diagnostic platform, the company has successfully used Cchek to detect the presence of Melanoma in patients that have been diagnosed via conventional means, such as invasive procedures like biopsies.

Approximately 232,000 new cases of Melanoma are diagnosed each year worldwide. The 5-year survival rate for localized Melanoma is 98%, but declines to 63% and 17% for regional and distant stage disease, respectively. The company previously announced success with Cchek detecting Breast Cancer, Lung Cancer, and Colorectal Cancer.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment